Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.
The company's lead investigational product candidate, certepetide, is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively.
Executive Interviews
Lisata Therapeutics CEO Dr David Mazzo on global product license deal with Catalent
Executive Interviews
Lisata Therapeutics and GATC Health see collaboration as the way forward for drug development
